Hsp90 inhibitors as senolytic drugs to extend healthy aging

Area of Science:

• Gerontology and cellular biology
• Molecular mechanisms of aging
• Therapeutic interventions for age-related diseases

Background:

• Aging involves biological decay and is a primary risk factor for chronic diseases and cancer.
• Accumulated senescent cells contribute significantly to aging and age-related pathologies.
• Eliminating senescent cells in mice has improved age-related conditions.

Purpose of the Study:

• To highlight the importance of senotherapeutic strategies for aging.
• To review current senolytic and senomorphic drugs.
• To discuss novel senolytics targeting HSP90 co-chaperones.

Main Methods:

• Review of existing literature on senolytics and senomorphics.
• Analysis of therapeutic approaches targeting senescent cells.
• Focus on inhibitors of HSP90 co-chaperones as a novel senolytic class.

Main Results:

• Senotherapeutic approaches, including senolytics and senomorphics, are significant for aging.
• Various senotherapeutic drugs have been identified to date.
• Inhibitors of HSP90 co-chaperones represent a new class of senolytics.

Conclusions:

• Senotherapeutics offer a promising avenue to extend healthspan and potentially lifespan.
• Targeting senescent cells and their associated secretory phenotype is crucial for combating aging.
• HSP90 co-chaperone inhibitors are a notable advancement in senolytic drug development.